glp 1 drugs history Another milestone in the evolution of GLP-1-based diabetes therapies Upgrading from Overweight: The Effects

At 3 months, patients achieved an average weight loss of 5.9%, and at 6 months, the weight loss increased to 10.9%

9921019, Dec

These cases collectively suggest a potential link between semaglutide use and the development or exacerbation of depressive symptoms, warranting closer monitoring in clinical practice

doi: 10.1007/s40618-024-02466-4

Perhaps because of this lower threshold, 34 of the subjects were women

When a DPP-4 inhibitor is added to a sulfonylurea regimen, the sulfonylurea dose may need to be reduced Pioglitazone offers similar glycaemic efficacy to gliptins but is associated with fluid retention and fracture risk DPP-4 inhibitors are generally considered weight-neutral , which is an advantage over sulfonylureas and insulin